Dr. Lilja Solnes, Director of the Nuclear Medicine and Molecular Imaging division at Johns Hopkins, describes the mechanisms of this groundbreaking treatment that combines imaging and molecular radiotherapy. With this method, radiopharmaceuticals can be specifically targeted at cancer while leaving most normal tissues alone. Find out more at the Nuclear Medicine Radiotheranostic Center.
It's hard to describe how much it affects your life, not being able to leave the confines of your house. Ok. So this is a 2002 thunderbird that I restored. They only made 60,000 of them. This is the car that I go on all my road trips with. And three years ago I had to stop doing that four years ago. Uh because the symptoms, the cancer symptoms made it impossible to do it. Nice to see you. Hello. How's it going? How are you? When we met Bob, he was essentially home bound, had stopped traveling, stopped seeing friends. He had really given up all the things that he cared for or was interested in. The Carcinoid syndrome has a bunch of different symptoms. But mine, you have diarrhea, constant diarrhea. So I couldn't do anything. I was, I was pretty much, I was stuck in, I was a prisoner of mine, but I just stayed there didn't go anywhere. So I've had two liver resections down in Winchester and they've taken uh four or five tumors off the liver. Then they were gonna do another liver resection. I said, you know, I've I've had three operations. Now, I said, I don't wanna do this again. And I started doing research. I found the department in Hopkins. So I called up and said, I want a second opinion on this surgery. And I went up and I saw doctor Heat. He said, well, we don't think surgery is appropriate here. We got something we think is better for you. Theranos is a novel way to treat patients with cancer. What it is is we find a very specific target on a malignant tumor cell. If the patient expresses the target, which we can see by imaging, we're able to go in and treat them very specifically precisely treat the tumor uh of the patient and spare some of the normal tissue around. Once the specific target is identified, the therapeutic agent is injected intravenously into the forearm, then it navigates the bloodstream and finds the exact location on the tumor. The therapeutic agent is then internalized in the malignant cell where it's able to deliver a localized dose of radiation directly to the affected cell rather than more broadly treating the disease. And the location in which it presents with the first treatment about a month after the first treatment, things got dramatically better. And maybe two months, I was out having dinner with my son and his wife again and that doesn't sound like a whole lot. But you know, when you can't do it, it's uh going to a restaurant, it's pretty, pretty big deal. So Bob has done really well. We see him every six months, we do a scan with the diagnostic agent to see what his tumors look like. But given the remarkable response he's had so far, we expect that he'll do well four years ago before it got bad. I take road trips. I had to cross country a couple of times and, you know, just about every state. So, Doctor Soulis came in and we were talking and I told her, I said, you know, I, I'd love to take these road trips and I hadn't been able to take one. And I told her about the Grand Canyon and all that stuff and she said, well, hopefully you'll be able to do that now. And if you go, you better send us pictures and the Luther was the last hope for that. And luckily it worked.
Facebook
Twitter
YouTube
LinkedIn
Instagram
E-News
BROADCASTMED